



It's not TAVI, it's Evolut™

Durable clinical outcomes in low-risk patients at five years.^{†,1}



In low-risk patients at five years vs. surgery, only Evolut™ TAVI delivers

16% lower mean gradients¹

10.7 mmHg Evolut™ TAVI vs. 12.8 mmHg SAVR; p < 0.001

11% larger EOAs¹

2.1 cm² Evolut™ TAVI vs. 1.9 cm² SAVR

† Devices: Evolut™ R 73%/Evolut™ PRO 23.4%/CoreValve™ 3.6%.

1. Reardon M, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Aortic Stenosis Patients at Low Surgical Risk: 5-Year Outcomes from the Evolut Low Risk Trial. Presented at ACC; March 2025.

This material should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s). Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For an MRI compatible device(s), consult the MRI information in the device manual(s) before performing an MRI. If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com.

Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser. Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable).

For any further information, contact your local Medtronic representative and/or consult Medtronic's websites.

Medtronic

Europe
Medtronic International Trading Sarl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
Tel: +41 (0)21 802 70 00
Fax: +41 (0)21 802 79 00

medtronic.eu

©2025 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.

2025-low-risk-5yr-one-pager--emea-16764036
03/2025